Biotechnology News and Research

RSS

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

HemoShear announces research collaboration with Medivir

HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases.

23 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Interleukin Genetics, Inc. today announced it has received conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict™ Genetic Risk Test for periodontal disease.

22 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

New computational method speeds up estimates of gene activity from RNA-seq data

With gene expression analysis growing in importance for both basic researchers and medical practitioners, researchers at Carnegie Mellon University and the University of Maryland have developed a new computational method that dramatically speeds up estimates of gene activity from RNA sequencing (RNA-seq) data.

21 Apr 2014

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Cyclenium Pharma Inc., an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on proprietary macrocyclic chemistry, today announced the signing of a discovery and co-development agreement with Southern Research Institute, a not-for-profit 501(c)(3) scientific research organization founded in 1941.

18 Apr 2014

Researchers discover new marker derived from human umbilical cord blood

The development of stem cell therapies to cure a variety of diseases depends on the ability to characterize stem cell populations based on cell surface markers.

18 Apr 2014

13th annual Bio-IT World Conference & Expo to launch new disciplinary track on data security

The 13th annual Bio-IT World Conference & Expo, to be held April 29-May 1 at the Seaport World Trade Center in Boston, today announced that it will debut a new disciplinary track focused on data security.

18 Apr 2014

Food shortage will have serious implications for people and governments in the world

The world is less than 40 years away from a food shortage that will have serious implications for people and governments, according to a top scientist at the U.S. Agency for International Development.

17 Apr 2014

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma, today announced the completion of an agreement between Analytical Testing Laboratories (ATL), a Lebanon based company that specializes in drug testing services and inborn errors of metabolism, for the exclusive distribution of the company's amino acid based products to physicians and pharmacies throughout the Middle East.

17 Apr 2014

Nora Therapeutics closes $18M Series B financing to expand drug development

Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced the closing of an $18 million Series B financing.

17 Apr 2014

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

A class of drugs developed to treat immune-related conditions and cancer - including one currently in clinical trials for glioblastoma and other tumors - eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to UC Irvine researchers.

17 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Baxter International Inc. today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.

From Baxter International Inc. 16 Apr 2014

Harvard successfully transplants regenerated esophagus into rat using bioreactor

Harvard Apparatus Regenerative Technology, Inc., a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that a research team led by Paolo Macchiarini, MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by HART.

16 Apr 2014

Study: Bacterium that causes whooping cough changes in Australia

The bacterium that causes whooping cough, Bordetella pertussis, has changed in Australia - most likely in response to the vaccine used to prevent the disease - with a possible reduced effectiveness of the vaccine as a result, a new study shows.

16 Apr 2014

Kineta, RLB Holdings form joint venture to address unmet medical needs

Kineta, Inc., a biotechnology company focused on the development of immune-modulating drugs for critical diseases, and RLB Holdings, an investment fund founded by Ray and Lydia Bartoszek, have formed a joint venture, Kineta RLB, LLC, which will commercialize promising, high-value compounds in selective disease areas with unmet medical needs.

15 Apr 2014

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

15 Apr 2014

Biotechnology News and Research

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

HemoShear announces research collaboration with Medivir

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Interleukin receives conditional approval to offer results of PerioPredict genetic risk test

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

New computational method speeds up estimates of gene activity from RNA-seq data

Cyclenium Pharma signs drug discovery and development agreement with Southern Research Institute

Researchers discover new marker derived from human umbilical cord blood

13th annual Bio-IT World Conference & Expo to launch new disciplinary track on data security

Food shortage will have serious implications for people and governments in the world

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Nora Therapeutics closes $18M Series B financing to expand drug development

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

Iconic Therapeutics completes $20 million Series B-1 equity financing

Baxter reports topline results from BAX 111 Phase 3 trial for treatment of von Willebrand disease

Harvard successfully transplants regenerated esophagus into rat using bioreactor

Study: Bacterium that causes whooping cough changes in Australia

Kineta, RLB Holdings form joint venture to address unmet medical needs

Sanofi Korea launches gut health product, Probi Digestis

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News